AN2 Therapeutics, Inc. — SEC Form D Filing

AN2 Therapeutics, Inc. filed an SEC Form D on March 25, 2026, reporting $40.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
March 25, 2026
Amount reported
$40.00M
Industry
Pharmaceuticals
Website
https://www.an2therapeutics.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

AN2 Therapeutics addresses the need for new therapeutic options in treating infectious diseases and oncology.

Solution

They utilize their boron chemistry platform to develop novel boron-based compounds that aim to be best in class therapeutics.

Verdict

Investors backed AN2 Therapeutics because the promise of new therapeutic options for infectious diseases and oncology is a persistent need, not because the market was saturated with effective alternatives. Implicitly, they were betting on the uniqueness of boron chemistry in addressing these medical challenges, while acknowledging limited upside in terms of widespread adoption and competition from established therapies.

Source: SEC EDGAR Form D filing